Policy Priorities at ZERO
Key Issues for Patients and Families
ZERO fights on behalf men and their families to ensure that the government directs resources to prostate cancer that further our mission and does not implement policies that hinder the Journey to Generation ZERO, the first generation free from prostate cancer.
ZERO’s policy priorities are:
Protecting and growing research funding
- We urge Congress to increase funding for the PCRP from $110M in the FY2020 DoD appropriations bill. It's been 25 years since the federal government's most successful prostate cancer research initiative had $100M in funding. We are pleased that, through the efforts of ZERO Champions and the broader prostate cancer community, Congress is now funding the PCRP at its FY2001 level. We urge Congress to reach new heights in the fight against prostate cancer by increasing that level of funding in the FY2022 appropriations process by $10M.
- We urge Congress to support prostate cancer prevention and education funding. The President’s FY2020 budget request eliminates funding within the Centers for Disease Control and Prevention’s (CDC’s) comprehensive cancer control program for prostate cancer activities. This funding supports the development and dissemination of content to help patients and providers have a better-informed discussion about treatment options. It also provides needed funding for important surveillance activities that help providers, epidemiologists, and researchers better understand the disease, its incidence, and progression. The Labor-HHS-Education appropriations bills have
maintained funding for CDC prostate cancer activities in the last four years,
and we hope that support for the CDC will continue.
Additionally, we urge Congress to support an additional $2M to be used for a new CDC program to provide targeted outreach and education to high-risk men, including men with a family history and African-American men.
Advocating for early detection methods, recommendations, access to care, and coverage
- We urge Member of Congress to cosponsor the USPSTF Transparency and Accountability Act of 2019, which will be introduced by Reps. Phil Roe (R-TN) and Bobby Rush (D-IL). The bill would make significant changes to the U.S. Preventive Services Task Force (USPSTF), and the process the Task Force uses to make formal recommendations regarding preventive care services. It requires the involvement of specialists and stakeholders in the recommendation process, in addition to public comment periods on draft recommendations. The bill also trikes the language added by the Affordable Care Act that directly ties Medicare coverage of preventive services to the USPSTF gradings.
On May 8, 2018, the USPSTF released their final recommendation for the prostate-specific antigen (PSA) screening, upgrading their recommendation from a "D" grade to a "C" grade. The “C” grade, while an improvement on their previous recommendations, it is still not sufficient because it means that insurance companies: 1) Do not have to cover the PSA-test and 2) Can make patients pay for all or some of the screening even if the insurance company does cover the test.
- We urge the Veteran’s Health Administration to increase access to innovative prostate cancer diagnosis and treatment technology. Prostate cancer is the most commonly diagnosed cancer in the Veterans Health Administration (VHA). Currently, our Veterans are having difficulty accessing the most advanced technologies to help them receive optimal treatment. The lack of access is due to red tape and segmented budgets. ZERO calls on Congress to ensure our Veterans receive access to the technologies their physicians deem appropriate for evaluation and treatment.
Encouraging coordination among federal agencies
Raising education and awareness about prostate cancer issues at the federal, state, and local levels
- ZERO’s origins stem from grassroots advocacy efforts to secure federal funding for prostate cancer research. Each year during our Prostate Cancer Summit, passionate advocates like you descend on Capitol Hill in Washington, DC to continue fighting for policies that will end prostate cancer.
Through effective advocacy, we can influence the formation of achievable government policy and encourage elected officials to support our priorities. The constituent voice is a powerful one!
Become an advocate to end prostate cancer.